Dose-dense chemotherapy with trastuzumab is an appropriate option Journal Article

  

Authors:	Dang, C.; Norton, L.; Hudis, C.
Article Title:	Dose-dense chemotherapy with trastuzumab is an appropriate option
Keywords:	cancer chemotherapy; treatment outcome; clinical trial; doxorubicin; dose response; drug safety; monotherapy; side effect; note; paclitaxel; antineoplastic agent; letter; clinical practice; breast cancer; heart disease; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor 2; combination chemotherapy; cyclophosphamide; dose-response relationship, drug; breast neoplasms; monoclonal antibody; antibodies, monoclonal; clinical trials, phase iii as topic; cardiovascular risk; cardiotoxicity; breast tumor; phase 3 clinical trial; taxane derivative; trastuzumab; heart left ventricle ejection fraction
Journal Title:	Journal of Clinical Oncology
Volume:	26
Issue:	21
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2008-07-20
Start Page:	3655
End Page:	3656
Language:	English
DOI:	10.1200/jco.2008.17.5281
PUBMED:	18640949
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-49049104009&partnerID=40&md5=3d942202055bbbe6af5525b551c86a9d
Notes:	--- - "Cited By (since 1996): 1" - "Export Date: 17 November 2011" - "CODEN: JCOND" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/14266